Know Cancer

forgot password

A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma

Phase 2
21 Years
Open (Enrolling)
Solid Tumor Cancer, Renal Cell Carcinoma, Carcinoma, Renal Cell

Thank you

Trial Information

A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma

Inclusion Criteria

Inclusion criteria:

- Histologically or cytologically confirmed diagnosis of Renal Cell Carcinoma of
predominantly clear-cell histology (excluding chromophobe, papillary, collecting
duct, and undifferentiated tumors) which is metastatic or locally recurrent

- Either no prior systemic therapy or failed only 1 prior cytokine-based or
bevacizumab-based therapy

- Evidence of documented measurable disease by RECIST criteria

- Male or female at least 21 years of age

A woman is eligible to enter and participate in the study if she is of:

1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),
including any female who:

- Has had a hysterectomy,

- Has had a bilateral oophorectomy (ovariectomy),

- Has had a bilateral tubal ligation,

- Is post-menopausal (total cessation of menses for >= 1 year).

2. Childbearing potential, has a negative serum pregnancy test at Screening Period and
serum or urine pregnancy test at Day1, and agrees to use adequate contraception. GSK
acceptable contraceptive methods, when used consistently and in accordance with both
the product label and the instructions of the physician, are as follows:

- An intrauterine device (IUD) with a documented failure rate of less than 1% per

- Vasectomized partner who is sterile prior to the female subject's entry and is
the sole sexual partner for that female.

- Complete abstinence from sexual intercourse for 14 days before exposure to
investigation product, through the clinical trial, and for at least 21 days
after the last dose of investigational product.

- Double-barrier contraception (condom with spermicidal jelly, foam suppository,
or film; diaphragm with spermicide; or male condom and diaphragm with

A man with a female partner of childbearing potential is eligible to enter and participate
in the study if he uses a barrier method of contraception (e.g. condom) or abstinence
during the study and for 28 days following the last dose of investigational drug.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

- Adequate bone marrow function.

- Adequate hepatic function.

- Adequate renal function.

- Adequate PT/PTT or INR/aPTT.

- Able to swallow and retain oral medications.

- Written informed consent.

Exclusion criteria:

- Received prior non-cytokine or non-bevacizumab therapies .

- Received chemotherapy for renal cell carcinoma.

- Have had any major surgery, radiotherapy, or immunotherapy within the last 28 days
and/or not recovered from prior therapy.

- History of hypercalcemia within two months of start of therapy.

- Patients who are pregnant or lactating.

- Poorly controlled hypertension.

- QTc prolongation defined as a QTc interval ≥ 480 msecs or other significant ECG

- Has Class II, III or IV heart failure as defined by the New York Heart Association
functional classification system. A subject who has a history of Class II heart
failure and is asymptomatic on treatment may be considered eligible.

- Any history of cerebrovascular accident [CVA].

- History of myocardial infarction, admission for unstable angina, cardiac angioplasty
or stenting within the last 12 weeks.

- History of venous thrombosis in last 12 weeks.

- Current use of therapeutic warfarin.

- Use of antiplatelet agents other than aspirin (≤ 325 mg/day).

- Leptomeningeal or brain metastases.

- Prior history of malignancies other than renal cell carcinoma (except for basal cell
or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or
the subject has been free of any other malignancies for > 5 years).

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
(including lab abnormalities) that could interfere with subject safety or obtaining
informed consent.

- History of malabsorption syndrome, disease significantly affecting gastrointestinal
function or major resection of the stomach or small bowel that could affect
absorption, distribution, metabolism or excretion of study drugs. Has any unresolved
bowel obstruction or diarrhea.

- Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol.

- Is on any specifically prohibited medication or requires any of these medications
during treatment with GW786034.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Response by RECIST Criteria

Outcome Description:

The overall response is the number of participants who experience a confirmed complete (CR) or partial response (PR) of the total analysis population. Per the Response Evaluation Criteria In Solid Tumors (RECIST): CR = all detectable tumor has disappeared, PR = a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum, Progressive disease (PD) = a >=20% increase in target lesions, Stable Disease = small changes that do not meet previously given criteria.

Outcome Time Frame:

Baseline to Response (up to 3 years). Assessments occurred at Week 12 and every 8 weeks thereafter.

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Czech Republic: Státní ústav pro kontrolu léčiv, Oddělení klinického hodnocení

Study ID:




Start Date:

October 2005

Completion Date:

October 2012

Related Keywords:

  • Solid Tumor Cancer
  • Renal Cell Carcinoma
  • Carcinoma, Renal Cell
  • Angiogenesis
  • Renal Cell Carcinoma
  • Solid tumors
  • Pazopanib(GW786034)
  • Carcinoma
  • Carcinoma, Renal Cell



GSK Investigational Site Bakersfield, California  93309
GSK Investigational Site Indianapolis, Indiana  46260
GSK Investigational Site Akron, Ohio  44304
GSK Investigational Site Fort Worth, Texas  76104
GSK Investigational Site Savannah, Georgia  31405
GSK Investigational Site Germantown, Tennessee  38138
GSK Investigational Site Aurora, Colorado  80012